Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 4/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868920 | 0.83 | MTNR1A (0.40) | EEDMTNR1AHTR2AHTR2CGAA | |
| SCHEMBL14868927 | 0.78 | MTNR1A (0.39) | EEDMTNR1AHTR2AHTR2CGAA | |
| SCHEMBL14869476 | 0.74 | KDM4C (0.42) | EEDMTNR1AHTR2AHTR2CGAA | |
| SCHEMBL14868925 | 0.72 | P2RX7 (0.49) | EEDMTNR1AHTR2AHTR2CGAA | |
| SCHEMBL14868910 | 0.71 | MTNR1A (0.39) | EEDMTNR1AHTR2AHTR2CGAA | |
| SCHEMBL14869943 | 0.69 | MTNR1A (0.40) | EEDMTNR1AHTR2AHTR2CGAA | |
| SCHEMBL14872384 | 0.69 | MTNR1A (0.40) | EEDMTNR1AHTR2AHTR2CGAA | |
| SCHEMBL14869463 | 0.69 | CA1 (0.39) | EEDMTNR1AHTR2AHTR2CGAA | |
| SCHEMBL14868958 | 0.68 | MTNR1A (0.41) | EEDMTNR1AHTR2AHTR2CGAA | |
| SCHEMBL14869484 | 0.68 | CA1 (0.43) | EEDMTNR1AHTR2AHTR2CGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | EED 2710/4885MTNR1A 600/4885HTR2A 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.